Sani Kizilbash is an Oncology physician affiliated with Mayo Clinic. OpenAlex indexes 220 publications with 2,157 citations (h-index 20); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Rochester, MN 559050001
Telephone
507-284-2511Provider last certified this registry record 14 Aug 2020.
Clinical trials
- Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
- Novocure Inc.Program year20231 payment
- SK Life Science, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
78%PD-1 inhibitor23.8%Pembrolizumab100%Part B, office-administered≥31 patientsPlatinum-based Drug16.6%Oxaliplatin97%Carboplatin3%Part B, office-administered≥26 patients+ 6 more classes in this area
Metabolism & gastrointestinal
18.6%Other antiemetics14.6%Fosaprepitant100%Part B, office-administered≥30 patientsSerotonin-3 Receptor Antagonist4%Palonosetron hcl59%Ondansetron hydrochloride40%Ondansetron Hcl1%Part D + Part B≥79 patientsSensory organs
2.7%Corticosteroid2.7%Dexamethasone sodium phosphate99%Dexamethasone1%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2021–2024 per NIH RePORTER. The latest:
- Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU
Mayo Clinic Rochester
FY2024$297,510R01FD007288 - Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU
Mayo Clinic Rochester
FY2022$297,510R01FD007288 - Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FU
Mayo Clinic Rochester
FY2021$286,989R01FD007288
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”